|
Category:antioxidants, skin conditioning
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Boiling Point: | 649.02 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 655.00 °F. TCC ( 346.30 °C. ) (est)
|
| logP (o/w): | 11.327 (est) |
| Soluble in: |
| | water, 8.516e-009 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intramuscular-mouse LD50 > 1000 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
intraperitoneal-mouse LD50 > 10000 mg/kg
Yaoxue Tongbao. Bulletin of Pharmacology. Vol. 18, Pg. 97, 1983.
intravenous-mouse LD50 > 1000 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
oral-mouse LD50 > 20000 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
intramuscular-rat LD50 > 1000 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
intravenous-rat LD50 > 250 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
oral-rat LD50 > 15000 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 > 20000 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
subcutaneous-rat LD50 > 10000 mg/kg
Drugs in Japan Vol. 6, Pg. 508, 1982.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | antioxidants, skin conditioning |
| Recommendation for tocopheryl nicotinate usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for tocopheryl nicotinate flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: View |
| AIDS Citations:Search |
| Cancer Citations:Search |
| Toxicology Citations:Search |
| EPA ACToR:Toxicology Data |
| EPA Substance Registry Services (SRS):Registry |
| Laboratory Chemical Safety Summary :27990 |
| National Institute of Allergy and Infectious Diseases:Data |
| [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] pyridine-3-carboxylate |
| Chemidplus:0043119477 |
References:
| | [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] pyridine-3-carboxylate |
| NIST Chemistry WebBook: | Search Inchi |
| Canada Domestic Sub. List: | 43119-47-7 |
| Pubchem (cid): | 27990 |
| Pubchem (sid): | 134991868 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| (2R-(2R*(4R*,8R*)))-3,4- | dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl tridecyl)-2H-1-benzopyran-6-yl nicotinate | | [2R-2R*(4R*,8R*)]-3,4- | dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol nicotinate | | | juvela nicotinate | | 3- | pyridinecarboxylic acid, (2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl ester | | 3- | pyridinecarboxylic acid, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl ester, (2R-(2R*(4R*,8R*)))- | | (2R-(2R*(4R*,8R*)))-3- | pyridinecarboxylic acid, 3,4-dihydro-2,5,7,8tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl ester | | (2R)-2,5,7,8- | tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-yl nicotinate | | (2R)-2,5,7,8- | tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-yl pyridine-3-carboxylate | | [(2R)-2,5,7,8- | tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] pyridine-3-carboxylate | | DL-a- | tocopherol nicotinate | | (2R)-2-((4R,8R)-4,8,12- | trimethyltridecyl)-2,5,7,8-tetramethylchroman-6-yl pyridine-3-carboxylate | | | vitamin E nicotinate | | | vitamin E nicotinic acid ester |
Articles:
| PubMed:Final report on the safety assessment of Tocopherol, Tocopheryl Acetate, Tocopheryl Linoleate, Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl Tocopheryl Phosphate, and Tocophersolan. |
| PubMed:Structural characteristic of terminal dicarboxylic moiety required for apoptogenic activity of alpha-tocopheryl esters. |
| PubMed:Allergic contact dermatitis due to DL-alpha-tocopheryl nicotinate. |
| PubMed:Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. |
| PubMed:Final report on the safety assessment of Tocopherol, Tocopheryl Acetate, Tocopheryl Linoleate, Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl Tocopheryl Phosphate, and Tocophersolan. |
| PubMed:Enhancement by alpha-tocopheryl hemisuccinate of nitric oxide production induced by lypopolysaccharide and interferon-gamma through the upregulation of protein kinase C in rat vascular smooth muscle cells. |
| PubMed:Hemolytic anemia after methylene blue therapy for aniline-induced methemoglobinemia. |
| PubMed:A randomised, double masked, clinical trial of high dose vitamin A and vitamin E supplementation after photorefractive keratectomy. |
| PubMed:Hydrolysis of tocopheryl and retinyl esters by porcine carboxyl ester hydrolase is affected by their carboxylate moiety and bile acids. |
| PubMed:Reduction of tablet coloration at tableting for oily medicine (tocopheryl nicotinate). |
| PubMed:Application of calcium silicate for medicinal preparation. I. Solid preparation adsorbing an oily medicine to calcium silicate. |
| PubMed:Tissue alpha-tocopherol concentrations following supplementation with various forms of vitamin E in sheep. |
| PubMed:[The significance of lipoprotein(a) in assessment of risk for atherosclerosis]. |
| PubMed:Protection against carbon tetrachloride-induced hepatotoxicity by pretreating rats with the hemisuccinate esters of tocopherol and cholesterol. |
| PubMed:Effects of dietary vitamin E on clinical course and plasma glutamic oxaloacetic transaminase and glutamic pyruvic transaminase activities in hereditary hepatitis of LEC rats. |
| PubMed:Serum total cholesterol, high-density lipoprotein-cholesterol and triglyceride concentrations in lambs following supplementation with various forms of tocopherol. |
| PubMed:Vitamin E and cancer prevention: recent advances and future potentials. |
| PubMed:Bioavailability of vitamin E compounds in lambs. |
| PubMed:High-performance liquid chromatographic determination of alpha-tocopheryl nicotinate in cosmetic preparations. |
| PubMed:A prevention trial on cerebral infarction with dl-alpha-tocopheryl nicotinate--rationales for trial. The Alpha-Tocopheryl Nicotinate Prevention Study Group. |
| PubMed:Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate. |
| PubMed:Effects of vitamin E administration on platelet function in diabetes mellitus. |
| PubMed:Effects of dietary vitamin E supplement on gracile axonal dystrophy (gad) mice. |
| PubMed:A nutritional evaluation of vitamin E status in very low birth weight infants with respect to changes in plasma and red blood cell tocopherol levels. |
| PubMed:Alpha tocopheryl succinate inhibits melanocyte-stimulating hormone (MSH)-sensitive adenylate cyclase activity in melanoma cells. |
| PubMed:Influence of vitamin E on platelet survival. |
| PubMed:Effect of vitamin E on IgE antibody formation in mice. |
| PubMed:Metabolism of the nicotinic acid moiety of d,l-alpha-tocopheryl nicotinate. |
| PubMed:[Clinical effect of dentifrice containing dl-alpha-Tocopheryl nicotinate]. |
| PubMed:[A case with Bartter's syndrome associated with type II hyperlipidemia, increased fluidity of plasma VLDL and abnormal configuration of peripheral erythrocytes (author's transl)]. |
| PubMed:[Effects of soysterol, pantethine and dl-alpha-tocopheryl nicotinate on hyperlipemia in rats (author's transl)]. |
| PubMed:The effect of food on the absorption of alpha-tocopheryl nicotinate in beagle dogs and human volunteers. |
| PubMed:Cutaneous microcirculatory effects of various vasodilator agents on the conscious rabbit, with special regard to changes in the rhythmic property of vasomotion. |
| PubMed:Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. |
| PubMed:Antihypertensive action of d,l-alpha-tocopheryl nicotinate in rats. |
| PubMed:Inhibition of platelet aggregation by alpha-tocopherol and its nicotinate and acetate esters. |
| PubMed:Effects of dl-alpha-tocopheryl nicotinate on coronary circulation and development of coronary collateral vessels. |
| PubMed:Comparative double-blind trial of dl-alpha-tocopheryl nicotinate on vibration disease. |
| PubMed:A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Juvela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis. |
| PubMed:Phagocytosis of alpha-tocopheryl nicotinate by the reticuloendothelial system: a microautoradiographic study. |
| PubMed:Anti-hypertensive action of DL-alpha-tocopharyl esters in rats. |
| PubMed:Comparison of alpha-tocopheryl nicotinate and acetate on skin microcirculation. |
| PubMed:Comparative studies of the effects of alpha-tocopheryl nicotinate and the combination alpha-tocopheryl acetate and nicotinic acid. |
| PubMed:Tissue uptake and metabolism of d,l-3,4- 3 H 2 -a-tocopheryl nicotinate and d,l-a-tocopheryl-1',2'- 3 H 2 -acetate following intravenous administration. |
|
3D/inchi